Compositions for oral drug administration

Abstract

The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms. In various aspects, the invention provides compositions and methods for oral delivery in the form of a tablet.

What is claimed is: 
     
         1 . A method of increasing the bioavailability of an active ingredient in a subject comprising administering an absorption increasing amount of an alkylglycoside with the active ingredient, in solid dosage form, thereby increasing the bioavailability of the active ingredient in the subject. 
     
     
         2 . The method of  claim 1 , wherein the active ingredient is selected from the group consisting of phenylephrine, aspirin, naproxen sodium, brompheniramine (maleate), triprolidine, chlorpheniramine (maleate), dextromethorphan (HBr), guaifenesin, acetaminophen, pseudaphedrine, epinephrine, diphenhydramine, cimetidine, loratadine, ranitidine, famotidine, ketoprofen, omeprazole, clemastine, dimenhydrinate, ibuprofen, cyclizine (Marizine) or other pharmaceutically acceptable salts thereof or as combinations thereof. 
     
     
         3 . The method of  claim 1 , wherein the alkylglycoside has an alkyl chain comprising between 10 to 16 carbons. 
     
     
         4 . The method of  claim 3 , wherein the alkylglycoside is selected from the group consisting of dodecyl maltoside, tridecyl maltoside, tetradecyl maltoside, sucrose mono-dodecanoate, sucrose mono-tridecanoate, and sucrose mono-tetradecanoate. 
     
     
         5 . The method of  claim 4 , wherein the alkylglycoside is tetradecyl-beta-D-maltoside or dodecyl-beta-D-maltoside. 
     
     
         6 . The method of  claim 1 , wherein the solid dosage form is a tablet. 
     
     
         7 . The method of  claim 6 , wherein the tablet is administered via the oral delivery route. 
     
     
         8 . The method of  claim 1 , wherein C max  is 2, 3, 4, 5, 6, 7, 8 or 9-fold greater as compared to delivery without alkylglycoside. 
     
     
         9 . The method of  claim 1 , wherein the alkylglycoside concentration is between about 0.05% and 10% (w/v). 
     
     
         10 . The method of  claim 9 , wherein the alkylglycoside concentration is between about 0.05% and 1% (w/v). 
     
     
         11 . A pharmaceutical composition comprising:
 a) a phenylephrine; and   b) an absorption increasing amount of an alkylglycoside.   
     
     
         12 . The pharmaceutical composition of  claim 13 , wherein the alkylglycoside has an alkyl chain including between 10 to 16 carbons. 
     
     
         13 . The pharmaceutical composition of  claim 12 , wherein the alkylglycoside is selected from the group consisting of dodecyl maltoside, tridecyl maltoside, tetradecyl maltoside, sucrose mono-dodecanoate, sucrose mono-tridecanoate, and sucrose mono-tetradecanoate. 
     
     
         14 . The pharmaceutical composition of  claim 13 , wherein the alkylglycoside is dodecyl-beta-D-maltoside. 
     
     
         15 . The pharmaceutical composition of  claim 11 , wherein the alkylglycoside concentration is between about 0.05% and 10% (w/v). 
     
     
         16 . The pharmaceutical composition of  claim 15 , wherein the alkylglycoside concentration is between about 0.05% and 1% (w/v).